Tag:

AMRI

Latest Headlines

Latest Headlines

AMRI gets its desert branch back online after a profit-sapping outage

After a weather-related shutdown at a New Mexico facility helped tank its quarterly earnings, AMRI has rectified the issue, bringing its plant back online as it works to get back on the path to growth.

Plant power outage zaps the juice from AMRI's earnings

Earlier this year, AMRI paid $110 million for injectable drug specialist Oso Biopharmaceuticals Manufacturing, expecting to make some extra money in its contract manufacturing operations. Instead, a power loss at that company's facility in New Mexico was a big factor in it reporting a loss in the last quarter.

AMRI tanks on disappointing sales and a dimmer outlook

Contract drug developer AMRI watched its shares plummet after underperforming in the third quarter, an earnings miss the company blamed on declining demand, spiking costs and bad weather in the desert.

AMRI buys into proteomics to expand its discovery services

Contract drug developer AMRI is expanding its platform to include protein R&D, investing in a market the company expects to boom over the coming years.

AMRI swings to revenue growth amid a transitional year

Contract drug developer AMRI posted a 15% boost in its quarterly revenue, using M&A and manufacturing demand to help wean it off royalty cash.

AMRI eyes a big year after completing another buyout

Contract developer AMRI has closed its $110 million acquisition of drug manufacturer Oso Biopharmaceuticals, its second deal this year and one the company believes will help pad its annual revenue.

AMRI finishes second manufacturing buy in 3 months

AMRI is building up its contract manufacturing operations and has completed a $110 million deal for Oso Biopharmaceuticals Manufacturing to add that company's expertise in complex injectable drug products to its stable.  

AMRI lays out $110M to buy Oso Biopharmaceuticals

AMRI said the Albuquerque, NM-based Oso will expand its capabilities in small-molecule and biologics manufacturing.

AMRI's paying $110M for a bolt-on CMO

In the midst of an ongoing reorganization, contract developer AMRI has made another buy in manufacturing, signing a deal to scoop up CMO OsoBio for $110 million in cash.

AMRI posts flat revenue as transitional year marches on

Contract drug developer AMRI turned in a stagnant revenue quarter, watching profits slip as it prepares to shake off its dependence on royalties and embrace a future in large-scale manufacturing.